Syndax Pharmaceuticals, Inc.
SNDXSyndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company is known for its use of epigenetic modulators, particularly histone deacetylase (HDAC) inhibitors, to enhance the effectiveness of immunotherapies and targeted treatments. Syndax's lead investigational drug, Axzagertib (formerly Entinostat), aims to improve outcomes in various cancers by modulating the tumor microenvironment and overcoming resistance mechanisms.
Company News
Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet c...
Syndax Pharmaceuticals' CEO will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, discussing the company's innovative cancer therapies and pipeline developments.
The FDA approved Revuforj (revumenib) for treating relapsed or refractory acute myeloid leukemia with NPM1 mutation in adult and pediatric patients, marking the first and only therapy approved for multiple acute leukemia subtypes.
Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.
Syndax Pharmaceuticals will report its Q2 2025 financial results and host a conference call on August 4, 2025, providing an update on its innovative cancer therapies and ongoing clinical trials.
